À l’occasion de Japan Expo 2026, où les visiteurs naviguent entre applications mobiles, QR codes, contenus exclusifs et téléchargements rapides, la question de la sécurité numérique devient plus concrète que jamais. Sur Android, les usages s’intensifient au rythme des recherches de programmes,...
Depuis des années, les scientifiques soupçonnent certaines bactéries intestinales de favoriser le cancer colorectal. Mais une nouvelle étude révèle qu’elles pourraient elles-mêmes être manipulées par un acteur jusqu’ici passé sous les radars : un virus caché dans leur ADN. Une découverte qui...
À l’occasion de l’Asteroid Day, les recherches autour de l’espace, des astéroïdes et des enjeux scientifiques attirent un public toujours plus large. Entre vidéos pédagogiques, articles spécialisés, PDF techniques et plateformes éducatives, la navigation devient dense et parfois exposée à des...
The State Department is taking over much of the control of global health initiatives, for which critics say the department does not have the expertise.
À l’occasion d’ICML 2026, la sécurité des environnements de développement revient au centre des préoccupations. Les chercheurs et ingénieurs en intelligence artificielle manipulent chaque jour des bibliothèques, des jeux de données et des scripts parfois issus de sources externes. Dans ce flux...
Un nouveau cheval de Troie bancaire, baptisé Rokarolla, se propage sur Android en se faisant passer pour Google Play Protect, l'antivirus du système. Une fois installé, il prend le contrôle du téléphone pour viser les identifiants de 217 applications bancaires et de cryptomonnaies.
University of California, Irvine Innovates Therapeutic Vaccine Strategy to Combat Recurrent Genital Herpes
In a groundbreaking development that could transform the management of genital herpes, UC Irvine immunologist Lbachir BenMohamed has secured nearly $4 million in funding from the National Institutes of Health to advance a novel therapeutic vaccine approach. This ambitious five-year project aims to tackle recurrent genital herpes caused by herpes simplex virus type 2 (HSV-2), a persistent viral infection that affects over 60 million Americans and more than half a billion individuals globally. Despite extensive research efforts historically, no approved therapeutic vaccine exists to date, leaving millions vulnerable to recurrent outbreaks and transmission.
BenMohamed’s research focuses on a next-generation vaccine strategy termed “Prime/Pull/Keep,” designed to establish a robust, localized immune defense precisely at the mucosal sites where HSV-2 resides and reactivates. Conventional vaccines predominantly elicit circulating antibodies, which are insufficient to control HSV-2’s latent reservoirs in the nerve ganglia and mucosal tissues. This innovative approach instead targets tissue-resident memory T cells (TRM), a specialized subset of immune cells critically positioned at the barrier sites to provide immediate defense against viral reactivation.
The Prime/Pull/Keep methodology encompasses a three-step immunization process: initial priming of protective T cells via vaccination, mobilization of these cells to the infected tissue through chemokine signals (pull), and sustained retention and functional maintenance at the site of infection (keep). Together, these steps ensure a sustained population of antiviral T cells, capable of rapid detection and elimination of reactivated virus, potentially curbing recurrent disease manifestations and viral shedding.
Previous investigations by BenMohamed’s team have demonstrated promising results with mRNA-based therapeutic vaccines in preclinical models. These candidates were effective in reducing clinical signs of recurrent genital herpes and enhancing the recruitment of protective T cells within genital mucosal tissues. Additionally, exploring immune-signaling molecules such as chemokines has validated the feasibility of attracting and retaining TRM populations, thereby improving local immune surveillance and long-term antiviral immunity.
The current NIH-funded project intends to rigorously evaluate the safety profile and immunogenic potential of various Prime/Pull/Keep vaccine candidates in preclinical animal models, examining how augmenting the quantity, quality, and durability of TRM cells correlates with protection from HSV-2 reactivation. This represents a critical translational step toward bridging laboratory research and clinical trials, responding to NIH’s strategic priority to develop novel therapeutic interventions for genital herpes.
BenMohamed articulates the significance of this research succinctly: “People living with recurrent genital herpes have long awaited effective therapeutic vaccines. Our innovative immune-based approach not only amplifies protective T cells but directs and maintains them where the virus hides. This could revolutionize prevention strategies for millions affected worldwide.” The team’s vision is to develop a vaccine capable of reducing recurrent outbreaks and viral transmission, substantially improving quality of life for patients.
HSV-2 represents a formidable pathogen due to its ability to establish lifelong latent infection in sensory neurons, periodically reactivating to cause painful genital lesions and facilitating onward transmission. Existing antiviral therapies focus on suppressing viral replication but do not eliminate reservoirs or prevent recurrence. The targeted boosting of tissue-resident immune memory represents a paradigm shift in immunotherapy, promising durable tissue-specific immunity where it is needed most.
The Prime/Pull/Keep vaccination strategy could also circumvent issues faced by traditional systemic vaccines, which often fail to generate sufficient mucosal immunity or induce long-lasting memory T cell populations within genital tissues. By tailoring antigen delivery and immune modulation, this approach aims to enhance the local microenvironment and foster a self-renewing population of sentinel T cells poised to respond immediately to viral reactivation.
As the project advances through preclinical stages, rigorous assessment of immune correlates of protection will inform optimization of vaccine formulations, dosing schedules, and adjuvant combinations. Understanding the mechanisms underpinning TRM cell maintenance and functionality remains an active area of investigation critical to maximizing therapeutic efficacy and durability.
The successful identification of an optimal Prime/Pull/Keep candidate would pave the way for human clinical trials, marking a historic milestone in the fight against genital herpes. Such a vaccine holds the promise not only to alleviate recurrent symptoms but also to significantly curtail viral shedding, thereby decreasing transmission rates and public health burden.
Beyond genital herpes, the conceptual framework underlying Prime/Pull/Keep may inspire novel immunotherapeutic strategies for other persistent viral infections and chronic diseases where localized immune memory is pivotal. Collaborative efforts among immunologists, virologists, and clinical scientists will be essential to translate these findings into effective interventions.
With UC Irvine’s robust infrastructure, cutting-edge facilities, and interdisciplinary expertise, BenMohamed’s laboratory is well-positioned to spearhead this transformative endeavor. The $3.93 million NIH R01 grant underscores the scientific community’s confidence in this pioneering approach and its potential to redefine therapeutic vaccine development for chronic viral infections.
In conclusion, the UC Irvine-led Prime/Pull/Keep vaccine project represents a beacon of hope for millions plagued by recurrent genital herpes, offering a sophisticated and strategic means to harness the immune system’s power at the precise sites of viral latency and reactivation. As research progresses, the scientific world eagerly anticipates the realization of a durable, tissue-targeted therapeutic vaccine capable of changing the landscape of HSV-2 management and prevention.
Subject of Research: Development of a novel therapeutic vaccine to prevent recurrent genital herpes by targeting tissue-resident memory T cells
Web References:
– University of California, Irvine: www.uci.edu
– UC Irvine News: news.uci.edu
– NIH Media Resources: https://news.uci.edu/media-resources/
À l’occasion de l’Asteroid Day, de nombreux passionnés se tournent vers des vidéos, cartes du ciel, applications d’observation ou ressources pédagogiques pour approfondir leurs connaissances. Cette curiosité conduit souvent à multiplier les recherches, les téléchargements et les visites de sites...
À mesure que les projets logiciels gagnent en complexité, la protection des postes de travail devient un enjeu aussi important que la productivité. Entre les bibliothèques tierces, les extensions et les ressources téléchargées au quotidien, les développeurs sont exposés à des risques parfois...
760 000 morts par an. L'animal le plus meurtrier de la planète ne rugit pas, ne mord pas et tient dans le creux d'une main. Il bourdonne. Face à l'explosion de la dengue et du paludisme, des scientifiques étudient aujourd'hui des pistes radicales pour neutraliser les moustiques les plus...
Fini les vaccins à reformuler chaque année ? Une équipe de Cambridge teste une technologie révolutionnaire capable d’anticiper les mutations virales grâce à l’IA. Une avancée qui pourrait changer durablement notre réponse aux épidémies.
Les menaces numériques ne prennent plus forcément la forme d’attaques visibles. Elles s’installent parfois silencieusement, via un lien frauduleux, un fichier piégé ou une connexion détournée. Dans ce paysage où les risques évoluent constamment, Bitdefender adopte une approche différente :...
Aux États-Unis, un homme est mort de la rage quelques semaines après avoir reçu une greffe de rein. Il s’avère que son donneur avait été contaminé par un animal, mais n’avait pas été diagnostiqué.
Sur Internet, les menaces ne se présentent plus toujours sous la forme d’alertes évidentes. Elles s’invitent discrètement, parfois avant même qu’un site ne semble suspect ou qu’un fichier ne paraisse dangereux. Phishing, arnaques en ligne, liens frauduleux ou logiciels malveillants circulent...
The Bundibugyo virus, a little known type, previously had caused just two small outbreaks. Now it’s at the center of a rapidly widening epidemic in Africa.
The types of Ebola and hantavirus worrying officials are very different from the species identified decades ago, raising new questions about how to respond.
Login
